Crinetics Pharmaceuticals (CRNX) Return on Sales (2017 - 2026)

Crinetics Pharmaceuticals' Return on Sales history runs 10 years deep, the most recent figure standing at 0.23% for Q1 2026.

• On a quarterly basis, Return on Sales fell 291.0% year-over-year to 0.23% in Q1 2026; TTM through Mar 2026 was 0.21%, a 39.0% decrease from a year earlier, with the FY2025 full-year figure at 0.6%, up 226.0% from the prior year.
• Return on Sales slipped to 0.23% in Q1 2026 per CRNX's latest filing, from 0.2% in the prior quarter.
• Across five years, Return on Sales topped out at 2.68% in Q1 2025 and bottomed at 9.1% in Q3 2025.
• The 5-year median for Return on Sales is 0.52% (2023), against an average of 0.09%.
• Biggest YoY gain for Return on Sales was 863 bps in 2022; the steepest drop was 1086 bps in 2022.
• Year by year, Return on Sales stood at 0.63% in 2022, then slumped by 182 bps to 0.52% in 2023, then jumped by 69 bps to 0.16% in 2024, then retreated by 22 bps to 0.2% in 2025, then retreated by 17 bps to 0.23% in 2026.
• Per Business Quant, the three latest CRNX Return on Sales figures stand at 0.23% (Q1 2026), 0.2% (Q4 2025), and 9.1% (Q3 2025).